Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2020 – Wrap Up
ASCO 2020 – Wrap Up
Clinical Activity of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion–Positive NSCLC
ASCO 2020 – Wrap Up
Results from the ARROW study showed that pralsetinib has rapid, potent, and durable clinical activity in patients with advanced
RET
fusion–positive non–small-cell lung cancer, regardless of
RET
fusion genotype or prior therapies.
Read More ›
Clinical Activity of the RET Inhibitor Pralsetinib (BLU-667) in Patients with RET-Altered Solid Tumors
ASCO 2020 – Wrap Up
Results from the ARROW study show that pralsetinib demonstrates broad and durable antitumor activity across multiple advanced solid tumor types, regardless of
RET
fusion genotype.
Read More ›
AcceleRET Lung: A Phase 3 Study of Pralsetinib in Patients with RET Fusion–Positive Metastatic NSCLC
ASCO 2020 – Wrap Up
The AcceleRET Lung study will evaluate the efficacy and safety of pralsetinib compared with standard of care for first-line treatment of patients with advanced/metastatic
RET
fusion–positive non–small-cell lung cancer.
Read More ›
Efficacy of Capmatinib in Second-Line Treatment of Patients with METex14-Mutated NSCLC
ASCO 2020 – Wrap Up
Results from the phase 2 GEOMETRY mono-1 study confirm capmatinib to be efficacious in second-line treatment of patients with
MET
exon 14–mutated non–small-cell lung cancer.
Read More ›
Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
ASCO 2020 – Wrap Up
An updated analysis of 3 phase 1/2 trials finds that entrectinib continues to demonstrate clinically meaningful responses in patients with
NTRK
fusion–positive solid tumors, including those with and without baseline central nervous system disease.
Read More ›
Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and Naïve RET-Driven Cancer Models
ASCO 2020 – Wrap Up
The next-generation RET inhibitor TPX-0046 demonstrates potent in vitro and in vivo activity against a diverse range of
RET
alterations, including solvent front mutation–mediated resistance.
Read More ›
Antitumor Activity of Selpercatinib (LOXO-292) in Patients with RET-Mutant Medullary Thyroid Cancer
ASCO 2020 – Wrap Up
Selpercatinib (LOXO-292) use was associated with durable antitumor activity in patients with
RET
-mutant medullary thyroid cancer previously treated with cabozantinib and/or vandetanib as well as in cabozantinib/vandetanib-naïve patients.
Read More ›
Liquid Biopsy Compared with Tissue Biopsy for Molecular Profiling in Patients with NSCLC
ASCO 2020 – Wrap Up
In newly diagnosed patients with lung cancer, liquid biopsy using the Guardant 360 assay identifies actionable targets beyond those identified by tumor tissue profiling alone and with a shorter turnaround time.
Read More ›
Efficacy of Amivantamab (JNJ-61186372) in Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation
ASCO 2020 – Wrap Up
Results from the CHRYSALIS study show that amivantamab demonstrates robust and durable antitumor activity and a manageable safety profile in patients with
EGFR
exon20ins-mutated non–small-cell lung cancer.
Read More ›
Barriers to Targeted Therapies for NSCLC Patients with Highly Actionable Gene Variants in the Veterans Health Affairs Program
ASCO 2020 – Wrap Up
A substantial minority of patients with advanced non–small-cell lung cancer and highly actionable gene variants were not prescribed available targeted therapies in the Veterans Health Affairs National Precision Oncology Program.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us